Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation

BACKGROUND AND OBJECTIVES: The complement inhibitor eculizumab has dramatically improved the outcome of atypical hemolytic uremic syndrome. However, the optimal duration of eculizumab treatment in atypical hemolytic uremic syndrome remains debated. We report on the French atypical hemolytic uremic s...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin J Am Soc Nephrol
Main Authors: Fakhouri, Fadi, Fila, Marc, Provôt, François, Delmas, Yahsou, Barbet, Christelle, Châtelet, Valérie, Rafat, Cédric, Cailliez, Mathilde, Hogan, Julien, Servais, Aude, Karras, Alexandre, Makdassi, Raifah, Louillet, Feriell, Coindre, Jean-Philippe, Rondeau, Eric, Loirat, Chantal, Frémeaux-Bacchi, Véronique
Format: Artigo
Jezik:Inglês
Izdano: American Society of Nephrology 2017
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5220663/
https://ncbi.nlm.nih.gov/pubmed/27799617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.06440616
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki